patient-system satisfaction (PSS) p¼ 0.94]. Of note, 10 prostate biopsy discussion encounters and 2 PSA follow-up encounters were carried out as part of the patients' active surveillance protocol. 8 prostate biopsy visits were carried out for discussion of a newly positive prostate biopsy result or an increase in the patient's Gleason Score with m PPS ¼ 4.88 and m PSS ¼ 4.88. For the remaining visits with no change in biopsy results, m PPS ¼ 5.0 and m PSS ¼ 4.5.
INTRODUCTION AND OBJECTIVES: Racial disparities in prostate cancer treatment and outcomes are a persistent public health problem. Communication between physician and patient about the clinical implications of prostate cancer and the trade-offs between different primary treatment options remains critical to prostate cancer management. To evaluate the communication about treatment options for prostate cancer, we assessed variation in the refusal of primary therapy among men diagnosed with prostate cancer from a national database.
METHODS: Using the National Cancer Database (NCDB), we identified all men diagnosed with localized prostate cancer from 2004 to 2013. The primary outcome was patient refusal of surgical or radiation therapy, annotated in the NCDB when recommended treatment was not performed with documentation of patient refusal. Multivariable logistic regression analysis was performed to determine clinical factors associated with patient refusal of primary therapy after meeting with a radiation oncologist or urologist. We also examined the association of all-cause mortality with refusal of therapy using Cox proportional hazards regression.
RESULTS: During the study interval, we identified 1,153,871 men diagnosed with localized prostate cancer. The median age was 65 years old. The most common primary therapies were surgery (55%) and radiation therapy (37%). Overall, 21,893 men refused any primary therapy (2.1%), which occurred in 2.0% of patients offered surgery and 2.5% of patients offered radiation. On multivariable analysis, African American (AA) men were more likely to refuse primary therapy compared to white men diagnosed with localized prostate cancer (OR:1.3; 95% CI 1.2-1.3). Similar findings were seen among patients with low income compared to high income (OR: 1.2; 95% CI 1. 16-1.23 Previous comparative effectiveness studies are limited by narrow inclusion criteria and outmoded treatments. Herein, we present 3-year functional outcomes in a diverse population of patients receiving contemporary treatment for localized PCa.
METHODS: The Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) study is a prospective, populationbased, cohort study of men diagnosed with localized PCa in 2011-2012. Men 80 years old or younger, with newly diagnosed cT1 or cT2 PCa, prostate specific antigen less than 50 ng/dL, were accrued from five Surveillance Epidemiology, and End Results (SEER) registry sites and from the Cancer of the Prostate Strategic Urologic Research Endeavor. Patient-reported urinary, sexual and bowel function, using the 26-item Expanded Prostate Index Composite (EPIC) at baseline, 6, 12, and 36 months after enrollment (range 0-100, higher score indicates better function).
RESULTS: The analytic cohort contained 2,543 men: 26% non-white; 45% low-risk, 39% intermediate risk, 16% high risk. 1,523 (59.9%) men underwent radical prostatectomy (RP), 599 (23.6%) external beam radiotherapy (EBRT), and 421 (16.6%) active surveillance (AS). At 3 years, sexual function after RP was significantly worse than EBRT (-17.1 points; 95% CI: -21.7 to -12.6; p<0.001), Figure. Differences in sexual function between EBRT and AS at 3 years, while statistically significant, were not clinically significant (-5.9 points; 95% CI -11.0 to -0.8; p¼0.023). RP was associated worse urinary continence scores than EBRT (-18 points; 95%CI: -20.6, -15.5; p<0.001) or AS (-13.4 points; 95% CI: -16.8, -10.1; p<0.001). At 3 years, 14% of RP men reported moderate or big problem with urinary leakage compared to 5% for EBRT and 6% for AS (p<0.001). Functional outcomes were driven largely by baseline function and treatment (Figure) . There were no clinically significant differences in bowel or hormone function and no difference in survival.
CONCLUSIONS: The effects of modern treatments are similar to the effects of older modalities noted in prior studies. This information will provide a foundation for shared decision making, rooted in contemporary population-based data. 
PD09-04 A RANDOMISED CONTROLLED FEASIBILITY STUDY: A MULTIMODAL SUPPORTIVE CARE INTERVENTION IN MEN AND THEIR PARTNERS/CARERS AFFECTED BY METASTATIC PROSTATE CANCER
Catherine Paterson*, Charlotte Primeau, Ghulam Nabi, Dundee, United Kingdom INTRODUCTION AND OBJECTIVES: A metastatic prostate cancer diagnosis and its treatments carry significant morbidity and related unmet supportive care needs. Such unmet needs have a profound decrement on patients and their families. We aimed to deliver at multimodal intervention based approach that targeted unmet needs for men and their partner/carers and compared this to current standard care.
METHODS: A two arm randomised controlled feasibility trial compared standard care to a multimodal supportive care intervention that combined an educational seminar on prostate cancer thrivership and individualized care from a designated prostate cancer specialist nurse. This involved in-depth assessment using patient reported outcome measures (PROMs) in routine clinical practice, followed up with a tailored plan of ongoing support to address informational, emotional, social and practical needs. 38 participants and 10 carers/ partners completed validated and reliable self-reported measures at baseline and at 3 months. 32 Semi-structured interviews were conducted with men, carers/partners and members of the multidisciplinary team. Self-efficacy was included as the potential moderator/mediator of intervention effect. Primary outcomes are unmet supportive care needs and quality of life. An economic evaluation was conducted alongside the randomised trial.
RESULTS: 29 participants in standard care arm (age 77.5, SD 6.2 years) identified a range of unmet supportive care needs related to physical, psychological/emotional, intimacy/sexual, practical, health system/informational, existential and patient/clinician communication needs. 19 participants (age 74.9, SD 8.2, years) in the interventions group, reported overall high satisfaction with the intervention and acceptance of PROMs in routine clinical practice, with less prevalence of unmet needs compared to standard care over time. Men and carers/ partners perceived that they had derived benefit from this model of care. Certain themes clearly emerged as important for participants, including being listened to by someone who could facilitate emotional expression, being provided with individually tailored information and receiving practical help and evidence-based advice for managing the consequences of cancer and its associated treatments. Significant cost-savings emerged in favour of the intervention.
CONCLUSIONS: This study has demonstrated that a multimodality supportive care intervention for men and their carer/partners affected by metastatic prostate cancer can achieve optimal supportive care. The active components of the intervention have been distinguished and provide the basis for the development of a larger sufficiently powered trial. One of the factors that may contribute to the slow progress in eliminating prostate cancer disparities among Black men is their underrepresentation in randomized controlled trials (RCTs) of new treatment modalities. We conducted this study to assess the current status of Black men's participation in RCTs for prostate cancer.
METHODS: We performed a protocol-driven systematic review for all published prostate cancer RCTs over a 25-year time period searching PUBMED. We only included RCTs of patients with an established diagnosis of prostate cancer and excluded studies of screening and diagnosis. For studies that resulted in multiple publications, only the initial study was included. We excluded secondary and subgroup analyses.
RESULTS: We found 584 unique trials that met the inclusion criteria, which we analyzed by type of intervention, sample size, disease stage, number of sites, origin, type of funding, publication year, the year enrollment began, and whether the study reported the inclusion of Black men. The median sample size of all trials was 125.5 (IQR ¼ 60-286.5) and the median number of sites was 5 (IQR ¼ 1-22). One hundred and eleven of the 584 (19.0%) trials worldwide and 81 of 189 (42.9%) of trials conducted exclusively within the US reported the enrollment of Black men. Of those trials that reported the inclusion of Black men, the median percentage of the study population was 10.55% overall (IQR ¼ 6.6%-19.8%) and 12.27% (IQR ¼ 7.0%-21.2%) for studies based exclusively in the United States. Among the 111 trials that reported the racial composition of participants, the median number of Black patients was 20 (IQR ¼ 8-37.5). In studies conducted exclusively within the US, the median number of black patients was 17 (IQR ¼ 8-31).
CONCLUSIONS: Less than 1 in 5 studies globally and half of studies from the US reported the participation of Black men. We found no study that enrolled Black men exclusively or that prospectively stratified analysis based on race. There is a critical need for greater involvement and better reporting of Black men's participation in prostate cancer trials.
